A Phase 3 interventional study of Fp MDPI and FS MDPI in Persistent Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 101 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-11-09.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one is the 14th largest by enrollment of the 146 interventional ones that give a count, is one of 9 that started in 2014, is one of 35 in phase 3, and was the 107th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 9 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 758 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
54 studies in Asthma by Teva Pharmaceutical Industries, Ltd.: none open now, 1 under way, 1 of them phase 3. Of 52 finished, 36 (69%) have results posted.
Among the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd., this one is the 11th largest by enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2014, is one of 30 in phase 3, and was the 33rd registered.
Teva Pharmaceutical Industries, Ltd.’s Asthma studies by the year they started, since 2003.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among Teva Pharmaceutical Industries, Ltd.’s 54 in Asthma:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the long-term safety of fluticasone propionate (Fp) inhalation powder in 2 strengths and fluticasone propionate/salmeterol inhalation (FS) powder in 2 strengths when administered with the Teva multidose dry powder inhaler (MDPI) device over 26 weeks in patients with persistent asthma.
This was a stratified, randomized, open-label, active drug-controlled Phase 3 study.
Patients who met all of the inclusion criteria and none of the exclusion criteria at the screening visit completed a 14 day (±2 days) pretreatment run in period. During the run-in period, patients continued using their current asthma medications (ie, inhaled corticosteroid and/or other controller therapies) except for their SABA, which was replaced by the sponsor-provided albuterol (salbutamol) hydrofluoroalkane (HFA) inhaler to be used as needed for symptomatic relief of asthma symptoms during the run in and treatment periods.
Patients were assigned to inhaled corticosteroid (ICS) monotherapy or inhaled corticosteroid/long acting beta2 agonist (ICS/LABA) combination therapy and then to a mid- or high-treatment strength based on their current asthma maintenance therapy regimen. Patients in each strength of the ICS monotherapy cohort were randomly assigned in a 3:1 distribution to either the Fp MDPI or FLOVENT HFA treatment arm. Patients in each strength of the ICS/LABA combination cohort were randomly assigned in a 3:1 distribution to either the FS MDPI or ADVAIR DISKUS treatment arm. There was a total of 8 treatment arms following randomization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female patients may not be pregnant, breastfeeding, or attempting to become pregnant.
Exclusion Criteria:
The patient has a disease/condition that in the medical judgment of the investigator would put the safety of the patient at risk through participation or that could affect the efficacy or safety analysis if the disease/condition worsened during the study.
Criteria for Randomization:
Patients were randomized into the study if they met all of the following criteria:
The patient complied with completion of the daily diary, defined as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg Fp for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid (ICS) cohort. Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
Drug: Fp MDPI · Drug: albuterol/salbutamol HFA
Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 440 mcg Fp for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort. Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
Drug: FLOVENT HFA · Drug: albuterol/salbutamol HFA
Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg Fp for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid (ICS) cohort. Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
Drug: Fp MDPI · Drug: albuterol/salbutamol HFA
Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 880 mcg Fp for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort. Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
Drug: FLOVENT HFA · Drug: albuterol/salbutamol HFA
Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 100/12.5 mcg for a total daily dose of 200/25 mcg FS for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort. Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
Drug: FS MDPI · Drug: albuterol/salbutamol HFA
Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 250/50 mcg for a total daily dose of 500/100 mcg FS for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort. Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
Drug: ADVAIR DISKUS · Drug: albuterol/salbutamol HFA
Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 200/12.5 mcg for a total daily dose of 400/25 mcg FS for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort. Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
Drug: FS MDPI · Drug: albuterol/salbutamol HFA
Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 500/50 mcg for a total daily dose of 1000/100 mcg FS for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort. Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
Drug: ADVAIR DISKUS · Drug: albuterol/salbutamol HFA
Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient. During the treatment period, participants were randomized to either 100 mcg or 200 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 400 mcg. Study drug was administered in the morning and in the evening.
Also known as: fluticasone propionate, inhaled corticosteroid
FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient. During the treatment period, participants were randomized to either Fp/Sx MDPI 100/12.5 mcg or Fp/Sx MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg Fp/Sx. Study drug was administered in the morning and in the evening.
Also known as: fluticasone propionate, inhaled corticosteroid, Salmeterol xinafoate, β2 adrenoceptor agonist
FLOVENT HFA is a hydrofluoroalkane (HFA) inhaler containing fluticasone propionate. During the treatment period, participants were randomized to either 110 mcg or 220 mcg of FLOVENT two puffs, twice a day for a total daily dose of 440 mcg or 880 mcg. Study drug was administered in the morning and in the evening.
Also known as: fluticasone propionate, inhaled corticosteroid
ADVAIR DISKUS contains a dry powder formulation of fluticasone propionate (Fp) and salmeterol xinafoate (Sx) in a lactose excipient. During the treatment period, participants were randomized to Fp 250 mcg/Sx 50 mcg or Fp 500 mcg/Sx 50 mcg one inhalation, twice a day for a total daily dose of 500/100 mcg or 1000/100 mcg. Study drug was administered in the morning and in the evening.
Also known as: fluticasone propionate, inhaled corticosteroid, salmeterol xinafoate, β2 adrenoceptor agonist
Drug page: Albuterol
A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Also known as: ProAir HFA, short-acting β2-adrenergic agonists
Participants With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
Time frame: Day 1 to Week 26 of the Treatment Period
Participants With Positive Swab Test Results for Oral Candidiasis
Oropharyngeal examinations for visual evidence of oral candidiasis were conducted at each visit by a qualified healthcare professional. Any visual evidence of oral candidiasis during the oropharyngeal exam was evaluated by obtaining and analyzing a swab of the suspect area. This outcomes indicates how many participants had positive swab test results. The total number of participants who had oropharyngeal exams at each timepoint are specified in the timepoint field. Appropriate therapy was to be initiated immediately at the discretion of the investigator and was not to be delayed for culture confirmation. Participants with a culture-positive infection could continue participation in the study on appropriate anti-infective therapy, provided this therapy was not prohibited by the protocol.
Time frame: Baseline (Day 1 pre-treatment), Weeks 2, 6, 10, 14, 18, 22 26, Endpoint
Participants With Potentially Clinically Significant Abnormal Vital Signs During the Treatment Period
Data represents participants with potentially clinically significant (PCS) vital sign values during the Treatment period. Significance criteria: * Systolic blood pressure - high: \>=180 and increase \>=20 mmHg * Systolic blood pressure - low: \<=90 and decrease \>=20 mmHg * Diastolic blood pressure - high: \>=105 and increase of \>=15 mmHg * Diastolic blood pressure - low: \<=50 and decrease of \>=15 mmHg * Pulse - high: \>=120 and increase of \>= 15 beats/minute from baseline * Pulse - low: \<=50 and decrease of \>=15 beats/minute
Time frame: Baseline (Day 1 pre-treatment), Weeks 2, 6, 10, 14, 18, 22 26, Endpoint
Shifts From Baseline to Endpoint in Electrocardiogram (ECG) Findings
A 12 lead ECG was conducted at the screening visit and week 26 or the early termination visit. A qualified physician at a central diagnostic center was responsible for interpreting the ECG. The worst post-baseline finding for the participant is summarized. Endpoint refers to the last observation carried forward.
Time frame: Screening (Day -14), Endpoint (week 26 if study was completed)
Analysis of 24-Hour Urine Cortisol Free Over the 26-Week Treatment Period
Samples for 24-hour urine cortisol were collected at baseline (Day 1, pretreatment), and Weeks 14 and 26. For participants requiring early termination (ET), this evaluation was performed at the ET visit. For participants requiring ET for safety reasons, the visit was not delayed in order to collect the 24-hour urine cortisol. The analysis is based on a mixed model for repeated measures (MMRM) model with adjustment for visit, treatment, and a treatment\*visit interaction. The urine cortisol result is log transformed prior to analysis and the results are back transformed after modeling. An unstructured covariance matrix is used in the MMRM model.
Time frame: Baseline (Day 1, pre-treatment), Weeks 14 and 26 and early termination visit if applicable
Change From Baseline in Trough Forced Expiratory Volume in 1 Minute (FEV1) Over the 26-Week Treatment Period
Spirometry measurements were obtained before the AM dose of study drug for the randomization visit (Day 1), at each of the treatment visits and at the early termination visit if applicable. At each visit where FEV1 was assessed, the highest acceptable results from each session were recorded. The analysis is based on a mixed model for repeated measures (MMRM) with adjustment for baseline FEV1, sex, age, (pooled) investigational center, visit, treatment, and treatment-by-visit. An unstructured covariance matrix is used in the MMRM model.
Time frame: Baseline (Day 1 pre-treatment), Weeks 2, 6, 10, 14, 18, 22 26, early termination visit if applicable
Of the 1087 patients screened, 758 patients at 103 investigational centers in the US met entry criteria. 331 patients were not enrolled: 267 due to inclusion/exclusion criteria, 21 withdrew consent, 9 were lost to follow up, 4 had an adverse event, and 30 patients had reason of 'other' or missing.
| Milestone | Enrolled Patients | Fp MDPI 100 mcg | FLOVENT HFA 110 mcg | Fp MDPI 200 mcg | FLOVENT HFA 220 mcg | FS MDPI 100/12.5 mcg | ADVAIR DISKUS 250/50 mcg | FS MDPI 200/12.5 mcg | ADVAIR DISKUS 500/50 mcg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 758 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 674 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 84 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomization criteria not met | 23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Exclusion criteria met | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Inclusion criteria not met | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Enrolled Patients | Fp MDPI 100 mcg | FLOVENT HFA 110 mcg | Fp MDPI 200 mcg | FLOVENT HFA 220 mcg | FS MDPI 100/12.5 mcg | ADVAIR DISKUS 250/50 mcg | FS MDPI 200/12.5 mcg | ADVAIR DISKUS 500/50 mcg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 127 | 42 | 126 | 41 | 120 | 41 | 133 | 44 |
| Completed | 0 | 111 | 35 | 113 | 36 | 110 | 36 | 116 | 38 |
| Not completed | 0 | 16 | 7 | 13 | 5 | 10 | 5 | 17 | 6 |
| Withdrew: Adverse event | 0 | 2 | 1 | 1 | 1 | 3 | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 9 | 3 | 6 | 2 | 4 | 2 | 9 | 2 |
| Withdrew: Noncompliance | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 3 | 1 | 3 | 1 | 2 | 1 | 2 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 3 | 1 | 0 | 0 | 2 | 0 |
An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
| Participants | Fp MDPI 100 mcg | FLOVENT HFA 110 mcg | Fp MDPI 200 mcg | FLOVENT HFA 220 mcg | FS MDPI 100/12.5 mcg | ADVAIR DISKUS 250/50 mcg | FS MDPI 200/12.5 mcg | ADVAIR DISKUS 500/50 mcg |
|---|---|---|---|---|---|---|---|---|
| >=1 TEAE | 85 | 29 | 83 | 29 | 92 | 29 | 86 | 30 |
| >=1 severe TEAE | 8 | 3 | 11 | 3 | 8 | 1 | 12 | 3 |
| >=1 treatment-related TEAE | 10 | 2 | 6 | 5 | 9 | 4 | 11 | 8 |
| >=1 severe treatment-related TEAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| >=1 serious TEAE | 7 | 2 | 8 | 3 | 6 | 2 | 13 | 3 |
| >=1 TEAE leading to withdrawal | 2 | 1 | 0 | 1 | 3 | 2 | 0 | 1 |
| >=1 nonserious TEAE | 85 | 27 | 82 | 29 | 91 | 28 | 85 | 29 |
| >=1 TEAE resulting in death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Oropharyngeal examinations for visual evidence of oral candidiasis were conducted at each visit by a qualified healthcare professional. Any visual evidence of oral candidiasis during the oropharyngeal exam was evaluated by obtaining and analyzing a swab of the suspect area. This outcomes indicates how many participants had positive swab test results. The total number of participants who had oropharyngeal exams at each timepoint are specified in the timepoint field. Appropriate therapy was to be initiated immediately at the discretion of the investigator and was not to be delayed for culture confirmation. Participants with a culture-positive infection could continue participation in the study on appropriate anti-infective therapy, provided this therapy was not prohibited by the protocol.
| Participants | Fp MDPI 100 mcg | FLOVENT HFA 110 mcg | Fp MDPI 200 mcg | FLOVENT HFA 220 mcg | FS MDPI 100/12.5 mcg | ADVAIR DISKUS 250/50 mcg | FS MDPI 200/12.5 mcg | ADVAIR DISKUS 500/50 mcg |
|---|---|---|---|---|---|---|---|---|
| Baseline (n=127, 42, 124, 41, 120, 41, 133, 44) | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 (n=123, 42, 123, 40, 117, 39, 131, 43) | 2 | 0 | 1 | 0 | 1 | 0 | 1 | 2 |
| Week 6 (n=119, 41, 119, 40, 115, 39, 125, 43) | 1 | 0 | 0 | 0 | 1 | 2 | 1 | 0 |
| Week 10 (n=119, 37, 118, 39, 115, 39, 120, 40) | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 |
| Week 14 (n=116, 36, 115, 38, 113, 38, 120, 41) | 1 | 0 | 1 | 1 | 2 | 0 | 1 | 1 |
| Week 18 (n=111, 37, 115, 38, 109, 38, 117, 40) | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Week 22 (n=110, 36, 113, 36, 110, 37, 116, 38) | 1 | 0 | 1 | 1 | 1 | 0 | 2 | 2 |
| Week 26 (n=111, 35, 113, 36, 110, 36, 116, 38) | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Endpoint (n=125, 42, 123, 41, 119, 40, 132, 44) | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
Data represents participants with potentially clinically significant (PCS) vital sign values during the Treatment period. Significance criteria: * Systolic blood pressure - high: \>=180 and increase \>=20 mmHg * Systolic blood pressure - low: \<=90 and decrease \>=20 mmHg * Diastolic blood pressure - high: \>=105 and increase of \>=15 mmHg * Diastolic blood pressure - low: \<=50 and decrease of \>=15 mmHg * Pulse - high: \>=120 and increase of \>= 15 beats/minute from baseline * Pulse - low: \<=50 and decrease of \>=15 beats/minute
| Participants | Fp MDPI 100 mcg | FLOVENT HFA 110 mcg | Fp MDPI 200 mcg | FLOVENT HFA 220 mcg | FS MDPI 100/12.5 mcg | ADVAIR DISKUS 250/50 mcg | FS MDPI 200/12.5 mcg | ADVAIR DISKUS 500/50 mcg |
|---|---|---|---|---|---|---|---|---|
| >=1 abnormality | 5 | 0 | 0 | 1 | 2 | 0 | 2 | 0 |
| Systolic blood pressure - high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Systolic blood pressure - low | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Diastolic blood pressure - high | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Diastolic blood pressure - low | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
| Pulse - high | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse - low | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A 12 lead ECG was conducted at the screening visit and week 26 or the early termination visit. A qualified physician at a central diagnostic center was responsible for interpreting the ECG. The worst post-baseline finding for the participant is summarized. Endpoint refers to the last observation carried forward.
| Participants | Fp MDPI 100 mcg | FLOVENT HFA 110 mcg | Fp MDPI 200 mcg | FLOVENT HFA 220 mcg | FS MDPI 100/12.5 mcg | ADVAIR DISKUS 250/50 mcg | FS MDPI 200/12.5 mcg | ADVAIR DISKUS 500/50 mcg |
|---|---|---|---|---|---|---|---|---|
| Baseline normal - Endpoint normal | 89 | 31 | 93 | 33 | 90 | 30 | 101 | 28 |
| Baseline normal - Endpoint abnormal | 8 | 5 | 6 | 1 | 9 | 2 | 8 | 3 |
| Baseline abnormal - Endpoint normal | 4 | 1 | 4 | 2 | 12 | 2 | 9 | 4 |
| Baseline abnormal - Endpoint abnormal | 11 | 2 | 13 | 3 | 5 | 4 | 7 | 4 |
Samples for 24-hour urine cortisol were collected at baseline (Day 1, pretreatment), and Weeks 14 and 26. For participants requiring early termination (ET), this evaluation was performed at the ET visit. For participants requiring ET for safety reasons, the visit was not delayed in order to collect the 24-hour urine cortisol. The analysis is based on a mixed model for repeated measures (MMRM) model with adjustment for visit, treatment, and a treatment\*visit interaction. The urine cortisol result is log transformed prior to analysis and the results are back transformed after modeling. An unstructured covariance matrix is used in the MMRM model.
| mcg/24 hours | Fp MDPI 100 mcg | FLOVENT HFA 110 mcg | Fp MDPI 200 mcg | FLOVENT HFA 220 mcg | FS MDPI 100/12.5 mcg | ADVAIR DISKUS 250/50 mcg | FS MDPI 200/12.5 mcg | ADVAIR DISKUS 500/50 mcg |
|---|---|---|---|---|---|---|---|---|
| Analysis of 24-Hour Urine Cortisol Free Over the 26-Week Treatment Period | 18.45 (15.77 to 21.58) | 13.94 (10.67 to 18.22) | 14.14 (12.23 to 16.34) | 17.50 (13.40 to 22.85) | 17.56 (15.13 to 20.38) | 18.29 (14.07 to 23.77) | 13.02 (11.23 to 15.09) | 15.42 (12.27 to 19.38) |
Spirometry measurements were obtained before the AM dose of study drug for the randomization visit (Day 1), at each of the treatment visits and at the early termination visit if applicable. At each visit where FEV1 was assessed, the highest acceptable results from each session were recorded. The analysis is based on a mixed model for repeated measures (MMRM) with adjustment for baseline FEV1, sex, age, (pooled) investigational center, visit, treatment, and treatment-by-visit. An unstructured covariance matrix is used in the MMRM model.
| liters | Fp MDPI 100 mcg | FLOVENT HFA 110 mcg | Fp MDPI 200 mcg | FLOVENT HFA 220 mcg | FS MDPI 100/12.5 mcg | ADVAIR DISKUS 250/50 mcg | FS MDPI 200/12.5 mcg | ADVAIR DISKUS 500/50 mcg |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Trough Forced Expiratory Volume in 1 Minute (FEV1) Over the 26-Week Treatment Period | 0.062 ± 0.0243 | 0.053 ± 0.0415 | 0.077 ± 0.0246 | 0.090 ± 0.0415 | 0.116 ± 0.0251 | 0.117 ± 0.0419 | 0.100 ± 0.0235 | 0.041 ± 0.0399 |
Collected over Day 1 to Week 26. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ADVAIR DISKUS 250/50 mcg | 0/41 (0%) | 2/41 (4.9%) | 22/41 (53.7%) |
| ADVAIR DISKUS 500/50 mcg | 0/44 (0%) | 3/44 (6.8%) | 23/44 (52.3%) |
| FLOVENT HFA 110 mcg | 0/42 (0%) | 2/42 (4.8%) | 24/42 (57.1%) |
| FLOVENT HFA 220 mcg | 0/41 (0%) | 3/41 (7.3%) | 25/41 (61%) |
| FS MDPI 100/12.5 mcg | 0/120 (0%) | 6/120 (5%) | 70/120 (58.3%) |
| FS MDPI 200/12.5 mcg | 0/133 (0%) | 13/133 (9.8%) | 68/133 (51.1%) |
| Fp MDPI 100 mcg | 0/127 (0%) | 7/127 (5.5%) | 65/127 (51.2%) |
| Fp MDPI 200 mcg | 0/125 (0%) | 8/125 (6.4%) | 55/125 (44%) |
| Event | ADVAIR DISKUS 250/50 mcg | ADVAIR DISKUS 500/50 mcg | FLOVENT HFA 110 mcg | FLOVENT HFA 220 mcg | FS MDPI 100/12.5 mcg | FS MDPI 200/12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg |
|---|---|---|---|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/41 | 2/44 | 0/42 | 0/41 | 3/120 | 8/133 | 6/127 | 4/125 |
| Atrial tachycardiaCardiac disorders | 0/41 | 0/44 | 0/42 | 1/41 | 0/120 | 0/133 | 0/127 | 0/125 |
| Device dislocationGeneral disorders | 0/41 | 0/44 | 0/42 | 1/41 | 0/120 | 0/133 | 0/127 | 0/125 |
| CellulitisInfections and infestations | 0/41 | 0/44 | 0/42 | 1/41 | 0/120 | 0/133 | 0/127 | 0/125 |
| Wound dehiscenceInjury, poisoning and procedural complications | 0/41 | 0/44 | 0/42 | 1/41 | 0/120 | 0/133 | 0/127 | 0/125 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/41 | 0/44 | 0/42 | 0/41 | 0/120 | 0/133 | 0/127 | 0/125 |
| FallInjury, poisoning and procedural complications | 0/41 | 0/44 | 1/42 | 0/41 | 0/120 | 0/133 | 0/127 | 0/125 |
| Hip fractureInjury, poisoning and procedural complications | 0/41 | 0/44 | 1/42 | 0/41 | 0/120 | 0/133 | 0/127 | 0/125 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/41 | 0/44 | 1/42 | 0/41 | 0/120 | 0/133 | 0/127 | 0/125 |
| Deep vein thrombosisVascular disorders | 0/41 | 0/44 | 1/42 | 0/41 | 0/120 | 0/133 | 0/127 | 0/125 |
| Event | ADVAIR DISKUS 250/50 mcg | ADVAIR DISKUS 500/50 mcg | FLOVENT HFA 110 mcg | FLOVENT HFA 220 mcg | FS MDPI 100/12.5 mcg | FS MDPI 200/12.5 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg |
|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 9/41 | 6/44 | 12/42 | 8/41 | 21/120 | 24/133 | 23/127 | 17/125 |
| SinusitisInfections and infestations | 4/41 | 8/44 | 3/42 | 3/41 | 9/120 | 14/133 | 15/127 | 6/125 |
| NasopharyngitisInfections and infestations | 4/41 | 4/44 | 7/42 | 5/41 | 15/120 | 12/133 | 17/127 | 13/125 |
| InfluenzaInfections and infestations | 2/41 | 1/44 | 2/42 | 5/41 | 7/120 | 3/133 | 10/127 | 8/125 |
| Oral candidiasisInfections and infestations | 2/41 | 5/44 | 0/42 | 5/41 | 5/120 | 5/133 | 6/127 | 5/125 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/41 | 4/44 | 5/42 | 1/41 | 7/120 | 9/133 | 13/127 | 6/125 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/41 | 1/44 | 3/42 | 4/41 | 14/120 | 8/133 | 10/127 | 13/125 |
| HeadacheNervous system disorders | 4/41 | 2/44 | 2/42 | 1/41 | 9/120 | 3/133 | 5/127 | 6/125 |
| Back painMusculoskeletal and connective tissue disorders | 2/41 | 0/44 | 0/42 | 3/41 | 1/120 | 3/133 | 1/127 | 1/125 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 3/41 | 0/44 | 0/42 | 1/41 | 7/120 | 2/133 | 1/127 | 2/125 |
Safety population which included all randomized participants who received at least 1 dose of randomized study drug
| Age, Customized(Participants) | Fp MDPI 100 mcg | FLOVENT HFA 110 mcg | Fp MDPI 200 mcg | FLOVENT HFA 220 mcg | FS MDPI 100/12.5 mcg | ADVAIR DISKUS 250/50 mcg | FS MDPI 200/12.5 mcg | ADVAIR DISKUS 500/50 mcg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adolescents (12-17 years) | 19 | 7 | 16 | 3 | 13 | 5 | 9 | 1 | 73 |
| Adults (18-64 years) | 96 | 32 | 96 | 35 | 94 | 31 | 106 | 41 | 531 |
| Adults (65+ years) | 12 | 3 | 12 | 3 | 13 | 5 | 18 | 2 | 68 |
| Missing | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
| Sex/Gender, Customized(Participants) | Fp MDPI 100 mcg | FLOVENT HFA 110 mcg | Fp MDPI 200 mcg | FLOVENT HFA 220 mcg | FS MDPI 100/12.5 mcg | ADVAIR DISKUS 250/50 mcg | FS MDPI 200/12.5 mcg | ADVAIR DISKUS 500/50 mcg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Male | 49 | 16 | 46 | 16 | 36 | 21 | 61 | 21 | 266 |
| Female | 78 | 26 | 78 | 25 | 84 | 20 | 72 | 23 | 406 |
| Missing | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Fp MDPI 100 mcg | FLOVENT HFA 110 mcg | Fp MDPI 200 mcg | FLOVENT HFA 220 mcg | FS MDPI 100/12.5 mcg | ADVAIR DISKUS 250/50 mcg | FS MDPI 200/12.5 mcg | ADVAIR DISKUS 500/50 mcg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Not Hispanic or Latino | 118 | 39 | 100 | 33 | 99 | 36 | 112 | 39 | 576 |
| Hispanic or Latino | 9 | 3 | 24 | 8 | 21 | 5 | 20 | 5 | 95 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Missing | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Fp MDPI 100 mcg | FLOVENT HFA 110 mcg | Fp MDPI 200 mcg | FLOVENT HFA 220 mcg | FS MDPI 100/12.5 mcg | ADVAIR DISKUS 250/50 mcg | FS MDPI 200/12.5 mcg | ADVAIR DISKUS 500/50 mcg | Total |
|---|---|---|---|---|---|---|---|---|---|
| White | 110 | 26 | 99 | 36 | 99 | 32 | 95 | 31 | 528 |
| Black or African American | 16 | 13 | 22 | 5 | 19 | 9 | 31 | 12 | 127 |
| Asian | 1 | 1 | 1 | 0 | 2 | 0 | 4 | 0 | 9 |
| American Indian or Alaskan Native | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 3 |
| Pacific Islander | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 3 |
| Other | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Missing | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
| History of Smoking(Participants) | Fp MDPI 100 mcg | FLOVENT HFA 110 mcg | Fp MDPI 200 mcg | FLOVENT HFA 220 mcg | FS MDPI 100/12.5 mcg | ADVAIR DISKUS 250/50 mcg | FS MDPI 200/12.5 mcg | ADVAIR DISKUS 500/50 mcg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prior smoker | 26 | 10 | 20 | 5 | 23 | 7 | 24 | 8 | 123 |
| No tobacco use | 101 | 32 | 106 | 36 | 97 | 34 | 109 | 36 | 551 |
Showing the first 100 of 101 sites. Choose a country and city above to see the rest.
The record gives a start of Jul 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone
Teva Branded Pharmaceutical Products R&D, Inc. →